Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Itamar Medical names new CEO
Prior to joining Itamar Medical Dr Rubin was co-founder, vice president and general manager of NDS, a high tech subsidiary of Rupert Murodch’s News Corporation where he oversaw
Prior to joining Itamar Medical Dr Rubin was co-founder, vice president and general manager of NDS, a high tech subsidiary of Rupert Murodch’s News Corporation where he oversaw
Under the agreement, PacificGMP will manufacture and perform fill or finish of Actinium’s HuM195 monoclonal antibody for a Phase I/II clinical trial. A stability study of the final
Under the terms of the agreement, Debiopharm will pay Aurigene an upfront fee, as well as further payments according to predefined discovery, development and sales milestones. Rolland-Yves Mauvernay,
Under the agreement, Solvay Pharmaceuticals will make an upfront payment of $25 million and will make milestone payments to Depomed, subject to the fulfillment of future regulatory and
Dr Kamarck succeeds Charles Portwood, who has been appointed to the new role of executive vice president of technical operations and product supply operational excellence. Both positions will
The randomized, double-blind, placebo-controlled study achieved its primary endpoints, demonstrating that sodium oxybate significantly decreased pain and fatigue, and improved daily function, in patients with fibromyalgia. The 14-week
The approval is said to be a significant milestone for eltrombopag and the immune thrombocytopenic purpura (ITP) community, as eltrombopag is the first oral thrombopoietin receptor agonist approved
The Phase I/II trial is being conducted at The Institute of Cancer Research in London and managed by the Drug Development Office of Cancer Research UK, which is
As the divestment strategy is progressing, the company might concentrate all of its activities in its headquarters in Montreal and thus, further preserve its cash into 2009. The
The design of the Phase III trial of NMED-1077 is a randomized withdrawal, placebo-controlled, double-blind trial which is being conducted at multiple centers in the US. The study